Last Updated: May 1, 2026

Patent: 9,415,106


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,415,106
Title:α-form zinc-phthalocyanine nanowires having enhanced water solubility and water dispersibility, composite of an α-form zinc-phthalocyanine nanowire/phenothiazine, and method for preparing same
Abstract:The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the alpha-form zinc-phthalocyanine nanowires or the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine according to the present invention exhibit dual traits, i.e., photothermal and photodynamic traits in single molecules, they are very useful for the development of a multifunctional molecular system and can also be usefully applied to light therapy of cancers due to their good light therapeutic effects. Also, the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine itself can exhibit fluorescence to facilitate the introduction of an imaging system, so that diagnosis and treatment can be simultaneously performed using a single substance.
Inventor(s):Hee Cheul Choi, Hye Kyung Moon, Sang Ho Lee
Assignee: Pohang University of Science and Technology
Application Number:US14/347,603
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 9,415,106: Claims and US Patent Landscape for Competitive Targeting

What does US 9,415,106 claim?

No analysis can be produced because the underlying claim set, specification, inventors, assignee, priority chain, and prosecution history are not provided in the input. Without the actual claim text (or a complete bibliographic record that includes it), any “comprehensive and critical analysis” of claim scope, claim construction risk, novelty/obviousness positioning, and infringement/invalidity likelihood would be incomplete.

What is the patent’s legal and technical footprint in the US?

A landscape assessment requires, at minimum, these elements: the full US bibliographic data (assignee, invention title, filing dates, priority dates, status), the complete claim set, and the family identifiers (continuations/divisionals) to map related applications. None of that data is present here, so no complete landscape can be built that meets an investment-grade standard.

How broad are the independent claims and where do they sit in the prior-art map?

Claim-scope mapping depends on the actual independent claim language (preamble terms, structural limitations, method steps, parameter thresholds, and defined terms). Prior-art mapping also requires the relevant CPC/USPC classification and the assignee’s historical technology center. Without the claim text and bibliographic record, prior-art placement cannot be done accurately.

Which US competitors and patent families are most likely to collide with US 9,415,106?

To identify collision zones, the analysis must pull: (1) claim-element-level search terms, (2) cited references from the prosecution file and/or IDS, and (3) prosecution-result data such as rejections and amendments. No prosecution or cited-art record is included, so competitor identification would be speculative.

What validity risks are structurally implied by typical US prosecution patterns?

Validity risk analysis depends on the file history: office actions, claim amendments, and the grounds used (anticipation vs. obviousness; 35 USC 102 vs. 103). The record is not provided, so a critical analysis would not be anchored to actual arguments or examiner findings.

What are the licensing and freedom-to-operate (FTO) implications in the US?

FTO requires a real claim chart: the elements of US 9,415,106 mapped to likely products/processes, plus an invalidity overlay based on the strongest prior-art references and their dates. Without the claim set and a defined technology context, no FTO-ready conclusion can be made.

How should investors or R&D teams use the patent in a competitive strategy?

A usable strategy requires knowing: (1) what the claims actually cover, (2) where those elements are likely to be designed around, (3) whether the family includes continuation claim variants, and (4) whether there are active enforcement or reexamination/IBR flags. None of these are available from the prompt.

What can be concluded from the information provided?

Nothing can be concluded in a way that is complete, critical, and actionable without the patent’s claim text and bibliographic/prosecution data.


Key Takeaways

  • A comprehensive, critical claim analysis and US landscape review cannot be produced because the claim set and patent record for US 9,415,106 are not included.
  • Landscape collision mapping requires citation and classification data tied to the actual claim elements.
  • Validity and FTO implications require prosecution history and claim-to-practice mapping.

FAQs

1) Can you summarize US 9,415,106’s claim scope without the claim text?

No. Claim scope depends on exact claim language, defined terms, and limitations.

2) Can you identify key prior art for the patent without the cited references?

No. Prior art mapping requires the examiner-cited references or IDS disclosures to anchor the analysis.

3) Can you assess obviousness/anticipation risk without the prosecution record?

No. The risk assessment depends on office-action grounds and claim amendments.

4) Can you list competing patent families likely to infringe without an element-by-element claim chart?

No. Competitor selection requires claim-element search strategies and a technology context.

5) Can you evaluate licensing and enforcement prospects without knowing the current status and related family members?

No. Enforcement and licensing depend on active status, family continuations, and claim scope across variants.


References

[1] US Patent No. 9,415,106. (Not provided in the prompt.)

More… ↓

⤷  Start Trial

Details for Patent 9,415,106

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eusa Pharma (uk) Limited SYLVANT siltuximab For Injection 125496 April 23, 2014 9,415,106 2032-08-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.